ATE277352T1 - Einetenascin-c isoform als marker für neoplasmen - Google Patents

Einetenascin-c isoform als marker für neoplasmen

Info

Publication number
ATE277352T1
ATE277352T1 AT00925224T AT00925224T ATE277352T1 AT E277352 T1 ATE277352 T1 AT E277352T1 AT 00925224 T AT00925224 T AT 00925224T AT 00925224 T AT00925224 T AT 00925224T AT E277352 T1 ATE277352 T1 AT E277352T1
Authority
AT
Austria
Prior art keywords
isoform
eintenascin
neoplasms
marker
ctn
Prior art date
Application number
AT00925224T
Other languages
English (en)
Inventor
Luciano Zardi
Original Assignee
Philogen Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philogen Spa filed Critical Philogen Spa
Application granted granted Critical
Publication of ATE277352T1 publication Critical patent/ATE277352T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
AT00925224T 1999-04-20 2000-04-19 Einetenascin-c isoform als marker für neoplasmen ATE277352T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999FI000094A IT1307864B1 (it) 1999-04-20 1999-04-20 Metodo diagnostico per il riconoscimento di neoplasie umane attraversola determinazione dell'isoforma ctn-c della tn-c, frammenti di
PCT/EP2000/003550 WO2000063699A1 (en) 1999-04-20 2000-04-19 A tenascin-c isoform as a marker for neoplasias

Publications (1)

Publication Number Publication Date
ATE277352T1 true ATE277352T1 (de) 2004-10-15

Family

ID=11352932

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00925224T ATE277352T1 (de) 1999-04-20 2000-04-19 Einetenascin-c isoform als marker für neoplasmen

Country Status (11)

Country Link
US (1) US7109301B1 (de)
EP (1) EP1173766B1 (de)
JP (1) JP4577665B2 (de)
AT (1) ATE277352T1 (de)
AU (1) AU779015B2 (de)
CA (1) CA2370666C (de)
DE (1) DE60014064T2 (de)
DK (1) DK1173766T3 (de)
ES (1) ES2226823T3 (de)
IT (1) IT1307864B1 (de)
WO (1) WO2000063699A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1317108B1 (it) * 2000-12-06 2003-05-26 Philogen Srl Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso.
EP1401870A4 (de) * 2001-05-24 2006-04-19 Human Genome Sciences Antikörper gegen tumor necrosis factor delta (april)
WO2003044036A1 (en) * 2001-11-19 2003-05-30 Applied Molecular Evolution, Inc. Tumor specific monoclonal antibodies
EA013537B1 (ru) * 2004-11-09 2010-06-30 Филоген Спа Антитела к тенасцину-с человека и их применение
CN102037144B (zh) 2008-04-01 2013-09-25 生物检索技术股份有限公司 稳定化的核酸暗猝灭剂-荧光团探针
KR101653030B1 (ko) 2010-08-13 2016-08-31 로슈 글리카트 아게 항-테나신-c a２ 항체 및 이의 사용 방법
WO2017194441A1 (en) 2016-05-11 2017-11-16 F. Hoffmann-La Roche Ag Modified anti-tenascin antibodies and methods of use
JP7285076B2 (ja) 2016-05-11 2023-06-01 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｔｎｆファミリーリガンドトリマーとテネイシン結合部分とを含む抗原結合分子
GB201621806D0 (en) 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
WO2018178076A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
CN107058596A (zh) * 2017-06-19 2017-08-18 上海市第十人民医院 一种与恶性胶质瘤诊断相关的标志物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8547291A (en) * 1990-09-05 1992-03-30 Wistar Institute, The Monoclonal antibodies against tenascin
JPH0643167A (ja) * 1992-04-06 1994-02-18 Amano Pharmaceut Co Ltd 癌マーカーであるテネイシン及びその定量法
CA2194369C (en) * 1994-07-11 2004-08-31 Philip E. Thorpe Methods and compositions for the specific coagulation of vasculature
EP0781297A4 (de) * 1994-09-16 1999-05-19 Scripps Research Inst Cytotactin-derivate, welche neuronale verbindungen und das neuritenwachstum fördern und verfahren ihrer produktion und anwendung
JP3850492B2 (ja) * 1996-08-23 2006-11-29 独立行政法人理化学研究所 テネイシン誘導因子

Also Published As

Publication number Publication date
ITFI990094A0 (it) 1999-04-20
IT1307864B1 (it) 2001-11-19
JP4577665B2 (ja) 2010-11-10
EP1173766A1 (de) 2002-01-23
DE60014064D1 (de) 2004-10-28
DE60014064T2 (de) 2006-02-23
AU4401500A (en) 2000-11-02
CA2370666A1 (en) 2000-10-26
AU779015B2 (en) 2005-01-06
ES2226823T3 (es) 2005-04-01
JP2002542486A (ja) 2002-12-10
WO2000063699A1 (en) 2000-10-26
CA2370666C (en) 2010-06-01
EP1173766B1 (de) 2004-09-22
DK1173766T3 (da) 2005-01-31
ITFI990094A1 (it) 2000-10-20
US7109301B1 (en) 2006-09-19

Similar Documents

Publication Publication Date Title
ATE438719T1 (de) Spezifischer marker für prostatakrebs
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
CY1112458T1 (el) Ενα αντισωμα ειδικο για διαλυτο baff για χρηση στην αντιμετωπιση του καρκινου
EP0914155A4 (de) Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen
DK1192463T3 (da) Kit- og bindingsassay to radioaktiv mærkning
ATE432986T1 (de) Menschlicher rezeptor für tumor necrosis factor
DE602004019812D1 (de) Marker für neuromyelitis optica
ATE301676T1 (de) Antikörper gegen die ed-b domäne von fibronektin, solche antikörper enthaltende konjugate, und deren verwendung zur diagnose und therapie von angiogenese-assoziierten tumoren und krankheiten
BRPI9912227B1 (pt) método para diagnóstico precoce in vitro de carcinomas e de seus estágios iniciais e kit para realização do método.
DK1064303T3 (da) Monoklonale antistoffer, der er specifikke for det prostataspecifikke membranantigens ekstracellulære domæne
DE69717664D1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
CY1110923T1 (el) Συζυγη που περιλαμβανουν ενα αντισωμα ειδικο για την ed-β περιοχη της ινονεκτινης και η χρηση τους για τον εντοπισμο και την αντιμετωπιση ογκων
PT1137943E (pt) Metodo e reagentes para a deteccao de cancro
BR0112644A (pt) Método de identificar marcadores de câncer e usos destes no diagnóstico do câncer
DE60014064D1 (de) Einetenascin-c isoform als marker für neoplasmen
CY1108540T1 (el) Ταυτοποιηση θεραπευτικων ενωσεων
DE50207866D1 (de) Verwendung löslicher cytokeratin-1-fragmente in diagnostik
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
DE60032784D1 (de) Markerproteine für prostatakrebs
FR2806739B1 (fr) Genes impliques dans les maladies inflammatoires de l'intestin et leur utilisation
EP1451552A4 (de) Zum nachweisen von erkrankungen der brust geeignete reagenzien und verfahren
DE59709109D1 (de) Monoklonale antikörper gegen einen komplex aus humanem act und einer serinprotease
WO2001096599A3 (en) Methods for quantitative determination of b-fibronectin in biological fluids and tissues
ATE299739T1 (de) Neurokinin b vorläufer aus menschlicher plazenta
UA40839A (uk) Спосіб визначення ступеня сприйняття психологічного впливу у осіб чоловічої статі шляхом психохарактерологічного тестування

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1173766

Country of ref document: EP

REN Ceased due to non-payment of the annual fee